The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

17 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.EBI
Yamanouchi Pharmaceutical
Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography.EBI
Yamanouchi Pharmaceutical
N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor.EBI
Yamanouchi Pharmaceutical
N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists.EBI
Yamanouchi Pharmaceutical
Synthesis and NK1 receptor antagonistic activity of (+/-)-1-acyl-3-(3,4- dichlorophenyl)-3-[2-(spiro-substituted piperidin-1'-yl)ethyl]piperidines.EBI
Yamanouchi Pharmaceutical
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.EBI
Yamanouchi Pharmaceutical
Synthesis and pharmacological characterization of novel 6-fluorochroman derivatives as potential 5-HT1A receptor antagonists.EBI
Yamanouchi Pharmaceutical
Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.EBI
Yamanouchi Pharmaceutical
Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.EBI
Yamanouchi Pharmaceutical
Novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonists: synthesis and structure-activity relationships of 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-pyrido[2,3-b]pyrazinedione and related compounds.EBI
Yamanouchi Pharmaceutical
Heterocyclic compounds as inhibitors of Vanin-1 enzymeBDB
Pfizer
Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulatorsBDB
Laboratorios Del Dr. Esteve
Therapeutic hydroxyquinolonesBDB
The State University of New Jersey
Azabenzimidazole derivativesBDB
Boehringer Ingelheim International
Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.BDB
The Weizmann Institute of Science
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.BDB
Burnham Institute For Medical Research
Synthesis and SAR of potent LXR agonists containing an indole pharmacophore.BDB
Gsk